Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

Commitments and Contingencies (Details)			1 Months Ended		3 Months Ended	6 Months Ended	12 Months Ended
Commitments and Contingencies (Details)	Mar. 28, 2024 USD ($)	Oct. 27, 2023 USD ($)	Apr. 30, 2024 USD ($)	Jul. 31, 2019 USD ($)	Mar. 31, 2020 USD ($) milestone	Jun. 30, 2024 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2018 unit $ / shares	Mar. 27, 2024 USD ($)	Dec. 31, 2023 USD ($)	Jun. 30, 2021 USD ($)	Jun. 21, 2021 USD ($)	Jun. 09, 2021 USD ($)	May 28, 2021 USD ($)	Mar. 25, 2021 USD ($)	Feb. 03, 2020 USD ($)
Other Commitments [Line Items]
Contingent consideration						$ 5,000,000				$ 0
Payment received				$ 2,000,000
Period after public launch to terminate agreement				3 years
Percentage of net present value of royalty payments				75.00%
Aevi
Other Commitments [Line Items]
Milestone payment						0
AlmataBio Transaction
Other Commitments [Line Items]
Payments to acquire productive assets	$ 7,500,000		$ 7,500,000			7,500,000
Milestone payment due upon first patient dosed in a Phase 2 trial						5,000,000
Aevi
Other Commitments [Line Items]
Number of milestones \| milestone					2
Milestone payment due upon first patient dosed in a Phase 2 trial					$ 6,500,000
Milestone One \| AlmataBio Transaction
Other Commitments [Line Items]
Milestone payment due upon first patient dosed in a Phase 2 trial	5,000,000
Milestone One \| Aevi
Other Commitments [Line Items]
Milestone payment due upon first patient dosed in a Phase 2 trial																$ 2,000,000.0
Milestone Two \| AlmataBio Transaction
Other Commitments [Line Items]
Milestone payment due upon first patient dosed in a Phase 2 trial	$ 15,000,000
Milestone Two \| Aevi
Other Commitments [Line Items]
Milestone payment due upon first patient dosed in a Phase 2 trial																4,500,000
Milestone Two \| AVTX-009
Other Commitments [Line Items]
Contingent consideration						5,000,000
Lilly License Agreement \| AVTX-009 Lilly License Agreement
Other Commitments [Line Items]
Milestone payments									$ 70,000,000
Maximum aggregate milestone payment									$ 650,000,000
Kyowa Kirin Co., Ltd. (KKC) \| AVTX-002 KKC License Agreement
Other Commitments [Line Items]
Upfront license fee															$ 10,000,000
Research and development expense						0
Cumulative expense recognized to date						0
Kyowa Kirin Co., Ltd. (KKC) \| AVTX-002 KKC License Agreement \| Milestone One
Other Commitments [Line Items]
Maximum aggregate milestone payment															112,500,000
Kyowa Kirin Co., Ltd. (KKC) \| AVTX-002 KKC License Agreement \| Milestone Two
Other Commitments [Line Items]
Maximum aggregate milestone payment															$ 75,000,000
CHOP License Agreement \| AVTX-002 KKC License Agreement
Other Commitments [Line Items]
Maximum aggregate milestone payment																900,000
Upfront license fee																500,000
Payments for legal settlements							$ 1,000,000
License fee																$ 200,000
Sanford Burnham Prebys Medical Discovery Institute \| AVTX-008 Sanford Burnham Prebys License Agreement
Other Commitments [Line Items]
Upfront license fee												$ 400,000
Research and development expense						0
Cumulative expense recognized to date						0
License fee											$ 100,000	40,000
Patent costs												500,000
Sanford Burnham Prebys Medical Discovery Institute \| AVTX-008 Sanford Burnham Prebys License Agreement \| Milestone One
Other Commitments [Line Items]
Maximum aggregate milestone payment												24,200,000
Sanford Burnham Prebys Medical Discovery Institute \| AVTX-008 Sanford Burnham Prebys License Agreement \| Milestone Two
Other Commitments [Line Items]
Maximum aggregate milestone payment												$ 50,000,000
Astellas Pharma, Inc. (Astellas) \| AVTX-006 Astellas License Agreement
Other Commitments [Line Items]
Maximum aggregate milestone payment						5,500,000
Upfront license fee						500,000
Research and development expense						0
Cumulative expense recognized to date						500,000
Alto \| AVTX-301 Out-License
Other Commitments [Line Items]
Maximum proceeds from milestones														$ 18,600,000
Revenue recognized from milestones to date						0
ES \| AVTX-406 License Assignment
Other Commitments [Line Items]
Revenue recognized from milestones to date						$ 0
ES \| Milestone One \| AVTX-406 License Assignment
Other Commitments [Line Items]
Maximum proceeds from milestones													$ 6,000,000
ES \| Milestone Two \| AVTX-406 License Assignment
Other Commitments [Line Items]
Maximum proceeds from milestones													$ 20,000,000
AUG Therapeutics, LLC \| Purchase Agreement \| AVTX-800 Series Asset Sale
Other Commitments [Line Items]
Upfront payment paid		$ 200,000
Asset acquisition consideration transferred, liabilities		$ 400,000
Contingent milestone upfront payment percentage		0.20
Contingent milestone payment		$ 15,000,000
Maximum potential payments		$ 45,000,000
TRIS Pharma \| Karbinal Agreement
Other Commitments [Line Items]
Minimum quantity required \| unit								70,000
Make whole payment per unit (in dollars per share) \| $ / shares								$ 30